A new study suggests that semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected benefit for people with type 2 diabetes. Researchers found that patients taking the medication experienced fewer bone fractures and greater weight loss than those using several other anti-obesity treatments.
The findings were presented Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Illinois.
According to the study, semaglutide use was linked to a 15% lower risk of bone fractures compared with alternative weight-loss medications. Although the results point to a possible protective effect on bone health, researchers say additional prospective studies are needed to confirm the association.
Semaglutide, Weight Loss, and Bone Health
Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1s), which are commonly prescribed to treat obesity and type 2 diabetes.
